Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Journal of neuro-oncology - 1 Jun 2014

Minniti Giuseppe, Scaringi Claudia, Arcella Antonella, Lanzetta Gaetano, Di Stefano Domenica, Scarpino Stefania, Bozzao Alessandro, Pace Andrea, Villani Veronica, Salvati Maurizio, Esposito Vincenzo, Giangaspero Felice, Enrici Riccardo Maurizi

Abstract excerpt

Several molecular markers have been proposed as predictors of outcome in patients with high grade gliomas. We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012. Correlations between the isocitrate dehydrogenase 1 (IDH1) mutation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Dacarbazine

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Isocitrate Dehydrogenase

Share to Temozolomide

Source

Identifiers

PMID: 24748470
DOI: 10.1007/s11060-014-1443-0

Genes

IDH1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.PMID 24748470Read ↗

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.Semantic proximity Read ↗

Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.Semantic proximity Read ↗

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastomaSemantic proximity Read ↗

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.Semantic proximity Read ↗

Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.Semantic proximity Read ↗

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapySemantic proximity Read ↗

Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.Semantic proximity Read ↗

IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas.Semantic proximity Read ↗

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.Semantic proximity Read ↗

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytomaSemantic proximity Read ↗

A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951Semantic proximity Read ↗

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.